Compare BKTI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | NGNE |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.7M | 327.8M |
| IPO Year | 2000 | 2014 |
| Metric | BKTI | NGNE |
|---|---|---|
| Price | $84.25 | $22.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $74.00 | $60.13 |
| AVG Volume (30 Days) | 24.4K | ★ 155.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 446.15 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $74,094,000.00 | $925,000.00 |
| Revenue This Year | $12.00 | N/A |
| Revenue Next Year | $11.30 | N/A |
| P/E Ratio | $37.16 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $26.33 | $6.88 |
| 52 Week High | $89.50 | $37.27 |
| Indicator | BKTI | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 60.56 |
| Support Level | $74.50 | $19.44 |
| Resistance Level | $87.21 | $24.53 |
| Average True Range (ATR) | 4.11 | 2.14 |
| MACD | 0.07 | 0.61 |
| Stochastic Oscillator | 52.78 | 60.99 |
BK Technologies Corp a holding company, operates through its subsidiary, BK Technologies, Inc., specializing in designing, manufacturing, and marketing wireless communications equipment. Its Radio business unit offers two-way land mobile radios (LMRs) serving government and public safety markets, as well as industrial and commercial enterprises. The SaaS business unit focuses on public safety smartphone applications, enhancing first responders' safety and efficiency. The BKRplay application, tethered to BK radios, amplifies user capabilities, expanding the reach of their radio sales. Its product portfolio consists of two-way land mobile radios, handheld radios, radios installed in vehicles.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.